Profiling MicroRNA from Brain by Microarray in a Transgenic Mouse Model of Alzheimer's Disease

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2017 Oct 24

PMID 29057267

Citations 29

Authors

Lin-Lin Wang

Li Min

Qing-Dong Guo

Jun-xia Zhang

Hai-Lun Jiang

Shuai Shao

Jian-Guo Xing

Lin-Lin Yin

Jiang-Hong Liu

Rui Liu

Shui-Long Guo

Affiliations

Soon will be listed here.

Abstract

MicroRNAs (miRNAs) are small noncoding RNAs, which regulate numerous cell functions by targeting mRNA for cleavage or translational repression, and have been found to play an important role in Alzheimer's disease (AD). Our study aimed to identify differentially expressed miRNAs in AD brain as a reference of potential therapeutic miRNAs or biomarkers for this disease. We used amyloid precursor protein (APP) and presenilin 1 (PS1) double transgenic mice and age-matched wild-type (WT) littermates to determine the expression of miRNAs in the brain. MiRNAs were profiled by microarray, and differentially expressed miRNAs underwent target prediction and enrichment analysis. Microarray analysis revealed 56 differentially expressed miRNAs in AD mouse brain, which involved 39 miRNAs that were significantly upregulated and 19 that were downregulated at different ages. Among those miRNAs, a total of 11 miRNAs, including miR-342-3p, miR-342-5p, miR-376c-3p, and miR-301b-3p, were not only conserved in human but also predicted to have targets and signaling pathways closely related to the pathology of AD. In conclusion, in this study, differentially expressed miRNAs were identified in AD brain and proposed as biomarkers, which may have the potential to indicate AD progression. Despite being preliminary, these results may aid in investigating pathological hallmarks and identify effective therapeutic targets.

Citing Articles

Apolipoprotein E dysfunction in Alzheimer's disease: a study on miRNA regulation, glial markers, and amyloid pathology.

Wijesinghe P, Li H, Ai Z, Campbell M, Chen S, Xi J Front Aging Neurosci. 2025; 16:1495615.

PMID: 39744521 PMC: 11688329. DOI: 10.3389/fnagi.2024.1495615.

Extracellular Vesicle-Enriched miRNA-Biomarkers Show Improved Utility for Detecting Alzheimer's Disease Dementia and Medial Temporal Atrophy.

Chai Y, Strohm L, Zhu Y, Chia R, Chong J, Suresh D J Alzheimers Dis. 2024; 99(4):1317-1331.

PMID: 38788066 PMC: 11191453. DOI: 10.3233/JAD-230572.

Exosomal Dynamics and Brain Redox Imbalance: Implications in Alzheimer's Disease Pathology and Diagnosis.

Bir A, Ghosh A, Chauhan A, Saha S, Saini A, Bisaglia M Antioxidants (Basel). 2024; 13(3).

PMID: 38539849 PMC: 10968072. DOI: 10.3390/antiox13030316.

Roles of Non-Coding RNA in Alzheimer's Disease Pathophysiology.

Olufunmilayo E, Holsinger R Int J Mol Sci. 2023; 24(15).

PMID: 37569871 PMC: 10420049. DOI: 10.3390/ijms241512498.

Kawakita R, Takata T, Nonaka W, Hamada Y, Iwama H, Kobara H Mol Med Rep. 2023; 28(2).

PMID: 37326032 PMC: 10308455. DOI: 10.3892/mmr.2023.13032.

References

Sonoda Y, Mukai H, Matsuo K, Takahashi M, Ono Y, Maeda K . Accumulation of tumor-suppressor PTEN in Alzheimer neurofibrillary tangles. Neurosci Lett. 2010; 471(1):20-4. DOI: 10.1016/j.neulet.2009.12.078. View

Qiu L, Zhang W, Tan E, Zeng L . Deciphering the function and regulation of microRNAs in Alzheimer's disease and Parkinson's disease. ACS Chem Neurosci. 2014; 5(10):884-94. DOI: 10.1021/cn500149w. View

Bagyinszky E, Youn Y, An S, Kim S . The genetics of Alzheimer's disease. Clin Interv Aging. 2014; 9:535-51. PMC: 3979693. DOI: 10.2147/CIA.S51571. View

Hara N, Kikuchi M, Miyashita A, Hatsuta H, Saito Y, Kasuga K . Serum microRNA miR-501-3p as a potential biomarker related to the progression of Alzheimer's disease. Acta Neuropathol Commun. 2017; 5(1):10. PMC: 5282710. DOI: 10.1186/s40478-017-0414-z. View

Kim J, Yoon H, Basak J, Kim J . Apolipoprotein E in synaptic plasticity and Alzheimer's disease: potential cellular and molecular mechanisms. Mol Cells. 2014; 37(11):767-76. PMC: 4255096. DOI: 10.14348/molcells.2014.0248. View

Zheng G, Jia X, Peng C, Deng Y, Yin J, Zhang Z . The miR-491-3p/mTORC2/FOXO1 regulatory loop modulates chemo-sensitivity in human tongue cancer. Oncotarget. 2015; 6(9):6931-43. PMC: 4466660. DOI: 10.18632/oncotarget.3165. View

Forner S, Baglietto-Vargas D, Martini A, Trujillo-Estrada L, LaFerla F . Synaptic Impairment in Alzheimer's Disease: A Dysregulated Symphony. Trends Neurosci. 2017; 40(6):347-357. DOI: 10.1016/j.tins.2017.04.002. View

Liu N, Zhuang Y, Zhou Z, Zhao J, Chen Q, Zheng J . NF-κB dependent up-regulation of TRPC6 by Aβ in BV-2 microglia cells increases COX-2 expression and contributes to hippocampus neuron damage. Neurosci Lett. 2017; 651:1-8. DOI: 10.1016/j.neulet.2017.04.056. View

Li X, Liu Y, Granberg K, Wang Q, Moore L, Ji P . Two mature products of MIR-491 coordinate to suppress key cancer hallmarks in glioblastoma. Oncogene. 2014; 34(13):1619-1628. PMC: 4205227. DOI: 10.1038/onc.2014.98. View

10.

Satoh J . Molecular network of microRNA targets in Alzheimer's disease brains. Exp Neurol. 2011; 235(2):436-46. DOI: 10.1016/j.expneurol.2011.09.003. View

11.

Lewis B, Burge C, Bartel D . Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005; 120(1):15-20. DOI: 10.1016/j.cell.2004.12.035. View

12.

Fang M, Wang J, Zhang X, Geng Y, Hu Z, Rudd J . The miR-124 regulates the expression of BACE1/β-secretase correlated with cell death in Alzheimer's disease. Toxicol Lett. 2011; 209(1):94-105. DOI: 10.1016/j.toxlet.2011.11.032. View

13.

Daly 4th J, Kotwal G . Pro-inflammatory complement activation by the A beta peptide of Alzheimer's disease is biologically significant and can be blocked by vaccinia virus complement control protein. Neurobiol Aging. 1999; 19(6):619-27. DOI: 10.1016/s0197-4580(98)00100-6. View

14.

Xu H, Cai T, Carmona G, Abuhatzira L, Notkins A . Small cell lung cancer growth is inhibited by miR-342 through its effect of the target gene IA-2. J Transl Med. 2016; 14(1):278. PMC: 5037891. DOI: 10.1186/s12967-016-1036-0. View

15.

Deng Y, Ding Y, Hou D . Research status of the regulation of miRNA on BACE1. Int J Neurosci. 2013; 124(7):474-7. DOI: 10.3109/00207454.2013.858249. View

16.

Krek A, Grun D, Poy M, Wolf R, Rosenberg L, Epstein E . Combinatorial microRNA target predictions. Nat Genet. 2005; 37(5):495-500. DOI: 10.1038/ng1536. View

17.

Latta C, Brothers H, Wilcock D . Neuroinflammation in Alzheimer's disease; A source of heterogeneity and target for personalized therapy. Neuroscience. 2014; 302:103-11. PMC: 4602369. DOI: 10.1016/j.neuroscience.2014.09.061. View

18.

Lugli G, Cohen A, Bennett D, Shah R, Fields C, Hernandez A . Plasma Exosomal miRNAs in Persons with and without Alzheimer Disease: Altered Expression and Prospects for Biomarkers. PLoS One. 2015; 10(10):e0139233. PMC: 4591334. DOI: 10.1371/journal.pone.0139233. View

19.

Barritt J, Viles J . Truncated Amyloid-β(11-40/42) from Alzheimer Disease Binds Cu2+ with a Femtomolar Affinity and Influences Fiber Assembly. J Biol Chem. 2015; 290(46):27791-802. PMC: 4646025. DOI: 10.1074/jbc.M115.684084. View

20.

Tan L, Yu J, Hu N, Tan L . Non-coding RNAs in Alzheimer's disease. Mol Neurobiol. 2012; 47(1):382-93. DOI: 10.1007/s12035-012-8359-5. View